In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.20.
Semenkow covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Sensei Biotherapeutics, and Editas Medicine. According to TipRanks, Semenkow has an average return of -19.5% and a 33.33% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sensei Biotherapeutics with a $6.00 average price target.
See today’s best-performing stocks on TipRanks >>
SNSE market cap is currently $31.87M and has a P/E ratio of -0.82.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SNSE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.
Read More on SNSE:
- Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Sensei Biotherapeutics reports Q2 EPS (31c) vs (34c) last year
- Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
- Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
- Sensei Biotherapeutics to host KOL event on SNS-101
